tiprankstipranks
Advertisement
Advertisement

ANAB Stock Latest News

AnaptysBio price target raised to $90 from $85 at Leerink
The FlyAnaptysBio price target raised to $90 from $85 at Leerink
15h ago
GSK
ANAB
AnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow
PremiumCompany Announcements
AnaptysBio Split Raises Execution, Cost and Governance Risks as Royalty Dependence and Valuation Uncertainty Grow
2d ago
ANAB
AnaptysBio price target raised to $76 from $60 at UBS
PremiumThe Fly
AnaptysBio price target raised to $76 from $60 at UBS
3d ago
ANAB
AnaptysBio price target raised to $75 from $63 at Barclays
PremiumThe Fly
AnaptysBio price target raised to $75 from $63 at Barclays
3d ago
ANAB
AnaptysBio reports Q1 EPS ($1.84), consensus (75c)
PremiumThe Fly
AnaptysBio reports Q1 EPS ($1.84), consensus (75c)
3d ago
ANAB
AnaptysBio Appoints New CFO and Board Director
PremiumCompany AnnouncementsAnaptysBio Appoints New CFO and Board Director
4d ago
8K
ANAB
AnaptysBio appoints Christopher Murphy as CFO
Premium
The Fly
AnaptysBio appoints Christopher Murphy as CFO
4d ago
ANAB
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
Premium
The Fly
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
12d ago
GSK
ANAB
AnaptysBio price target raised to $85 from $66 at Leerink
PremiumThe Fly
AnaptysBio price target raised to $85 from $66 at Leerink
18d ago
ANAB
GSK’s TESARO provides update on AnaptysBio litigation
PremiumThe Fly
GSK’s TESARO provides update on AnaptysBio litigation
19d ago
GSK
ANAB
Joseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
PremiumRatings
Joseph Thome Reiterates Buy on AnaptysBio as Royalty-Focused Model and Jemperli Legal Win Support $75 Price Target
19d ago
ANAB
Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
PremiumThe Fly
Delaware court dismisses Tesaro breach of contract claim against AnaptysBio
21d ago
GSK
ANAB
First Tracks Biotherapeutics initiated with an Outperform at Leerink
PremiumThe FlyFirst Tracks Biotherapeutics initiated with an Outperform at Leerink
22d ago
ANAB
TRAX
AnaptysBio price target lowered to $60 from $90 at UBS
Premium
The Fly
AnaptysBio price target lowered to $60 from $90 at UBS
24d ago
ANAB
AnaptysBio price target lowered to $63 from $79 at Barclays
Premium
The Fly
AnaptysBio price target lowered to $63 from $79 at Barclays
24d ago
ANAB
AnaptysBio price target lowered to $60 from $90 at UBS
PremiumThe Fly
AnaptysBio price target lowered to $60 from $90 at UBS
25d ago
GSK
ANAB
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
PremiumCompany Announcements
AnaptysBio Completes First Tracks Spin-Off, Refocuses on Royalties
25d ago
8K
ANAB
AnaptysBio completes separation of First Tracks Biotherapeutics
PremiumThe Fly
AnaptysBio completes separation of First Tracks Biotherapeutics
26d ago
ANAB
AnaptysBio price target raised to $95 from $67 at Piper Sandler
PremiumThe Fly
AnaptysBio price target raised to $95 from $67 at Piper Sandler
2M ago
ANAB
AnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
PremiumRatingsAnaptysBio: Spin-Off of First Tracks Bio and Strengthened Royalty Profile Create Attractive Risk-Reward Setup
2M ago
ANAB
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
Premium
Company Announcements
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
2M ago
8K
ANAB
AnaptysBio announces $100M share repurchase program
Premium
The Fly
AnaptysBio announces $100M share repurchase program
2M ago
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >